Theramir

Theramir is a Cyprus-based biotechnology company specializing in the development of microRNA (miRNA) based therapeutics and diagnostics for personalized cancer treatment. The company leverages its proprietary platform to identify and modulate specific miRNA sequences that drive tumor progression and resistance to therapy. Their pipeline includes miRNA mimics and inhibitors designed to restore normal cellular function or silence oncogenic pathways in various solid tumors. By combining targeted delivery systems with advanced molecular profiling, Theramir aims to provide more effective and less toxic treatment options for patients with hard-to-treat cancers. The company is currently advancing several programs through the pre-clinical stage, focusing on indications such as breast and colorectal cancer.